VTRS
Viatris Inc.
Viatris Inc. insider trading
Viatris Inc. files with the SEC as a Pharmaceutical Preparations company headquartered in Canonsburg, PA. Every time one of its executives or directors buys or sells the stock, the filing appears here the moment it reaches the SEC — with grants and option exercises set apart from the trades that cost the insider their own money.
From SEC filings
Recent VTRS insider transactions
One insider traded VTRS on the open market between Mar 23, 2026 and Jun 25, 2026 — 2 sales worth $1.1M, of which one was pre-scheduled under a 10b5-1 plan.
- Bought
- —
- Sold
- $1.1M
- Net
- −$1.1M
- Insiders
- 1
1 of 2 on a 10b5-1 plan
Campbell Paul10b5-1
See Remarks
−$809.8K
Jun 25, 2026
50,076 sh · $16.17
Campbell Paul
See Remarks
−$283.5K
Mar 23, 2026
21,350 sh · $13.28
| Date | Insider | Shares | Price | Value |
|---|---|---|---|---|
| Jun 25, 2026 | Campbell Paul10b5-1See Remarks | 50,076 | $16.17 | −$809.8K |
| Mar 23, 2026 | Campbell PaulSee Remarks | 21,350 | $13.28 | −$283.5K |
SEC Form 4 data, Q3 2024 to Q2 2026
VTRS insider trading by quarter
Between Jul 01, 2024 and Jun 30, 2026, 5 insiders traded VTRS on the open market: 4 purchases worth $761.4K and 11 sales worth $8.6M, 2 of the sales pre-scheduled under a 10b5-1 plan. In the last four quarters alone: 3 purchases ($225K) and 3 sales ($1.2M), by 4 insiders.
| Quarter | Bought | Sold | Insiders |
|---|---|---|---|
| Q2 2026 | — | −$809.7K1 sale · all on a plan | |
| Q1 2026 | — | −$283.5K1 sale | |
| Q4 2025 | +$2.2K1 buy | — | |
| Q3 2025 | +$222.8K2 buys | −$72.1K1 sale · all on a plan | |
| Q2 2025 | +$536.4K1 buy | — | |
| Q1 2025 | — | — | |
| Q4 2024 | — | −$346.8K1 sale | |
| Q3 2024 | — | −$7.1M7 sales |
- Largest purchase
- +$536.4K of VTRS by Smith Scott Andrew (Chief Executive Officer · Director) on May 12, 2025.
- Largest sale
- −$1.6M of VTRS by Malik Rajiv (Director) on Sep 12, 2024.
Open-market transactions through Jun 30, 2026most recent first
Campbell Paul10b5-1
Officer
−$809.7K
Jun 25, 2026
50,076 sh · $16.17
Campbell Paul
Chief Accounting Officer and Corporate Controller
−$283.5K
Mar 23, 2026
21,350 sh · $13.28
Simmons David S
Director
+$2.2K
Nov 03, 2025
213 sh · $10.43
Le Goff Corinne10b5-1
Chief Commercial Officer
−$72.1K
Sep 11, 2025
7,032 sh · $10.25
Simmons David S
Director
+$3K
Aug 27, 2025
286 sh · $10.42
Smith Scott Andrew
Chief Executive Officer · Director
+$219.8K
Aug 12, 2025
22,000 sh · $9.99
Smith Scott Andrew
Chief Executive Officer · Director
+$536.4K
May 12, 2025
60,000 sh · $8.94
Campbell Paul
Chief Accounting Officer and Corporate Controller
−$346.8K
Nov 11, 2024
26,925 sh · $12.88
Malik Rajiv
Director
−$1.6M
Sep 12, 2024
139,681 sh · $11.66
Malik Rajiv
Director
−$706.3K
Sep 12, 2024
60,319 sh · $11.71
Malik Rajiv
Director
−$600K
Aug 30, 2024
50,000 sh · $12.00
Malik Rajiv
Director
−$595K
Aug 28, 2024
50,000 sh · $11.90
Malik Rajiv
Director
−$1.2M
Aug 23, 2024
100,000 sh · $11.75
Malik Rajiv
Director
−$1.2M
Aug 22, 2024
100,000 sh · $11.73
Malik Rajiv
Director
−$1.2M
Aug 21, 2024
100,000 sh · $11.75
| Date | Insider | Shares | Price | Value |
|---|---|---|---|---|
| Jun 25, 2026 | Campbell Paul10b5-1Officer | 50,076 | $16.17 | −$809.7K |
| Mar 23, 2026 | Campbell PaulChief Accounting Officer and Corporate Controller | 21,350 | $13.28 | −$283.5K |
| Nov 03, 2025 | Simmons David SDirector | 213 | $10.43 | +$2.2K |
| Sep 11, 2025 | Le Goff Corinne10b5-1Chief Commercial Officer | 7,032 | $10.25 | −$72.1K |
| Aug 27, 2025 | Simmons David SDirector | 286 | $10.42 | +$3K |
| Aug 12, 2025 | Smith Scott AndrewChief Executive Officer · Director | 22,000 | $9.99 | +$219.8K |
| May 12, 2025 | Smith Scott AndrewChief Executive Officer · Director | 60,000 | $8.94 | +$536.4K |
| Nov 11, 2024 | Campbell PaulChief Accounting Officer and Corporate Controller | 26,925 | $12.88 | −$346.8K |
| Sep 12, 2024 | Malik RajivDirector | 139,681 | $11.66 | −$1.6M |
| Sep 12, 2024 | Malik RajivDirector | 60,319 | $11.71 | −$706.3K |
| Aug 30, 2024 | Malik RajivDirector | 50,000 | $12.00 | −$600K |
| Aug 28, 2024 | Malik RajivDirector | 50,000 | $11.90 | −$595K |
| Aug 23, 2024 | Malik RajivDirector | 100,000 | $11.75 | −$1.2M |
| Aug 22, 2024 | Malik RajivDirector | 100,000 | $11.73 | −$1.2M |
| Aug 21, 2024 | Malik RajivDirector | 100,000 | $11.75 | −$1.2M |
From SEC's quarterly Form 3, 4 and 5 data sets: code P purchases and code S sales of common stock, by the date the trade happened. Where a fund and the people who control it each report the same block, it is counted once. Trades made in the last days of Q2 2026 but filed after it closed arrive with SEC's next quarterly release.
Viatris Inc. company record
- SEC industry classification
- Pharmaceutical Preparations
- Headquarters
- Canonsburg, PA
- Incorporated in
- DE
- Listed on
- Nasdaq
- SEC Central Index Key
- 0001792044
- Previously filed as
- Upjohn Inc
Sourced from this company's own SEC submissions record. The industry label is SEC's Standard Industrial Classification, which is more specific than the Health Care sector shown above.
After insiders bought VTRS
What the stock actually did in the 90 days following each open-market purchase
Don't check VTRS — let it ping you
Get told the moment an insider moves on VTRS
Pro watches Viatris Inc. for you and sends a Telegram ping within moments of a Form 4 clearing EDGAR — a C-suite open-market buy, a cluster, a 10b5-1 regime break — long before it reaches the press. Add VTRS to a watchlist, see each mover's benchmark-measured track record and which legendary funds hold it, and read the full filing history instead of the last 72 hours.
The live dashboard is free to open. Alerts, watchlists, full filing history and each mover's benchmark-measured track record are Pro. Monitoring, not advice.
How to read VTRS insider activity
- Open-market purchase (code P)
- An insider spending their own money at market price. This is the only buy code that reliably carries signal — it is a decision, not compensation.
- Grants and option exercises (codes A, M)
- Scheduled compensation. Most "insider buying" headlines are really this, which is why InsiderPulse weights it at a fraction of a real purchase.
- Cluster buy
- Two or more different insiders buying on the open market in the same window. One executive buying can mean anything; three is much harder to explain away.
Other Health Care tickers
Questions
- Are VTRS insiders buying or selling?
- Between Mar 23, 2026 and Jun 25, 2026, 1 Viatris Inc. insider made no open-market purchases and 2 sales worth $1.1M, a net sale of $1.1M. 1 of the sales was pre-scheduled under a Rule 10b5-1 plan.
- How much VTRS stock have insiders bought and sold in the last two years?
- Between Jul 01, 2024 and Jun 30, 2026, 5 Viatris Inc. insiders made 4 open-market purchases worth $761.4K and 11 sales worth $8.6M. 2 of the sales were pre-scheduled under a Rule 10b5-1 plan. In the four quarters to Jun 30, 2026: 3 purchases ($225K) and 3 sales ($1.2M). The largest purchase was Smith Scott Andrew buying $536.4K on May 12, 2025. The largest sale was Malik Rajiv selling $1.6M on Sep 12, 2024.
- What was the largest recent VTRS insider trade?
- Campbell Paul (See Remarks) sold $809.8K of VTRS stock on Jun 25, 2026 at about $16.17 a share, under a pre-scheduled 10b5-1 plan.
- When did an insider last buy VTRS shares?
- No open-market purchase by a Viatris Inc. insider appears in the filings from Mar 23, 2026 to Jun 25, 2026 — every recorded open-market transaction in that period was a sale. Before that, the most recent purchase in SEC's data was Simmons David S buying $2.2K on Nov 03, 2025.
- Where does VTRS insider trading data come from?
- From the Form 4 filings Viatris Inc.'s officers, directors and 10% owners must send the SEC within two business days of a trade. Each row on this page links to its original filing on SEC EDGAR. Share grants and option exercises are kept apart from open-market purchases and sales, because only the latter cost the insider their own money.
Get the free Insider Brief
Each weekday evening: the day's biggest open-market insider buys, cluster formations and 10b5-1 plan breaks — in plain English, with grants and routine vesting stripped out. Honest about what the data can and cannot say.